REGNEarnings ReleaseSource checkedAugust 5, 2026by InvestLog AI

REGN earnings release — EPS beat +40.6% · revenue beat +12.4%Regeneron Pharmaceuticals, Inc. (REGN) 财报发布 — EPS 高于预期+40.6% · 营收高于预期+12.4%

Key Results

Regeneron Pharmaceuticals, Inc. (REGN) published results at 2026-07-30T10:48:32+00:00.

Actual vs Consensus

EPS: $14.29 vs $10.16 estimate, beat+40.6%.

Revenue: $4.3B vs $3.8B estimate, beat+12.4%.

Profitability and Cash Flow

Period: 2026 Q2

Revenue: $4.3B; YoY: +16.7%; QoQ: +19.0%

Gross profit: $3.7B; Gross margin: 86.6%

Operating income: $1.3B; Operating margin: 30.1%; YoY: +19.8%; QoQ: +121.0%

Net income: $1.3B; GAAP diluted EPS: $12.20; YoY: -6.8%; QoQ: +78.3%

Operating cash flow: $1.9B; Capex: $1M; Free cash flow: $1.9B

Cash: $2.5B; Total debt: $2.0B; Net cash: $469M

Official release: Reports Second Quarter 2026 Financial and Operating Results

核心结果

Regeneron Pharmaceuticals, Inc. (REGN) 已发布财报，发布时间：2026-07-30T10:48:32+00:00。

实际值与市场预期

EPS：$14.29 vs $10.16 预期，高于预期+40.6%。

营收：$4.3B vs $3.8B 预期，高于预期+12.4%。

财务指标

期间：2026 Q2

营收：$4.3B；同比：+16.7%；环比：+19.0%

毛利润：$3.7B；毛利率：86.6%

经营利润：$1.3B；经营利润率：30.1%；同比：+19.8%；环比：+121.0%

净利润：$1.3B；GAAP 稀释 EPS：$12.20；同比：-6.8%；环比：+78.3%

经营现金流：$1.9B；资本开支：$1M；自由现金流：$1.9B

现金：$2.5B；总债务：$2.0B；净现金：$469M

官方公告：Reports Second Quarter 2026 Financial and Operating Results

View REGN stock details ->查看 REGN 个股详情 ->

This earnings research was prepared from company results, regulatory filings, financial statements, and earnings-call transcripts or official replays. It is for informational purposes only and does not constitute investment advice.这篇财报研究基于公司业绩公告、监管文件、财务报表，以及财报电话会议记录或官方回放整理。内容仅供参考，不构成投资建议。

REGN earnings release — EPS beat +40.6% · revenue beat +12.4%Regeneron Pharmaceuticals, Inc. (REGN) 财报发布 — EPS 高于预期+40.6% · 营收 高于预期+12.4%